Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Herling

Showing results (1-10 of 173) with videos related to

Pageof 18
Sort By:
European Journal of Haematology|February 26, 2015
Are we improving the outcome for patients with T-cell prolymphocytic leukemia by allogeneic stem cell transplantation?Marco Herling
Acta Haematologica|May 6, 2020
What to Look Out for when Transplanting T-Cell Prolymphocytic LeukemiaLinus Wahnschaffe, Marco Herling
Blood|August 26, 2021
Altered epigenetics at the center of NK-LGL leukemiaMarco Herling, Linus Wahnschaffe
Blood Advances|February 3, 2025
PETAL: a global view on R/R T-/NK-lymphoma treatment realityQu Jiang, Marco Herling
Blood|June 10, 2021
Tracing the roots of CLPD-NK by TET2 and STAT3Marco Herling, Till Braun
American Journal of Clinical Pathology|April 19, 2007
CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cellsMarco Herling, Dan Jones
Blood|March 7, 2015
Multilevel BCR signals toward CLLMarco Herling, Elena Vasyutina
Blood|February 12, 2026
The ticking clock of relapse in T-cell lymphomasQu Jiang, Marco Herling
Hemasphere|June 7, 2021
Hijacking the Pathway: Perspectives in the Treatment of Mature T-cell LeukemiasLinus Wahnschaffe, Marco Herling
The Journal of Biological Chemistry|April 19, 2015
Interleukin-2-inducible T-cell kinase (ITK) targeting by BMS-509744 does not affect cell viability in T-cell prolymphocytic leukemia (T-PLL)Sabine Dondorf, Alexandra Schrader, Marco Herling
Pageof 18

Showing results (1-10 of 173) with videos related to

Sort By:
Pageof 18
European Journal of Haematology|February 26, 2015
Are we improving the outcome for patients with T-cell prolymphocytic leukemia by allogeneic stem cell transplantation?Marco Herling
Acta Haematologica|May 6, 2020
What to Look Out for when Transplanting T-Cell Prolymphocytic LeukemiaLinus Wahnschaffe, Marco Herling
Blood|August 26, 2021
Altered epigenetics at the center of NK-LGL leukemiaMarco Herling, Linus Wahnschaffe
Blood Advances|February 3, 2025
PETAL: a global view on R/R T-/NK-lymphoma treatment realityQu Jiang, Marco Herling
Blood|June 10, 2021
Tracing the roots of CLPD-NK by TET2 and STAT3Marco Herling, Till Braun
American Journal of Clinical Pathology|April 19, 2007
CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cellsMarco Herling, Dan Jones
Blood|March 7, 2015
Multilevel BCR signals toward CLLMarco Herling, Elena Vasyutina
Blood|February 12, 2026
The ticking clock of relapse in T-cell lymphomasQu Jiang, Marco Herling
Hemasphere|June 7, 2021
Hijacking the Pathway: Perspectives in the Treatment of Mature T-cell LeukemiasLinus Wahnschaffe, Marco Herling
The Journal of Biological Chemistry|April 19, 2015
Interleukin-2-inducible T-cell kinase (ITK) targeting by BMS-509744 does not affect cell viability in T-cell prolymphocytic leukemia (T-PLL)Sabine Dondorf, Alexandra Schrader, Marco Herling
Pageof 18